Hubei Yuanda Yongsheng Pharmaceutical

YuanDa Pharmaceuticals (Hubei) Co., Ltd., formerly known as Hubei Yuanda Yongsheng Pharmaceutical Co., Ltd., is a wholly-owned subsidiary of Grand Pharmaceutical (China) Co., Ltd. The company operates a major formulation manufacturing hub known as the Yongsheng Formulation Factory in Yangxin County, Hubei Province, which represents a significant strategic investment by Grand Pharma to expand its production capacity. YuanDa Pharmaceuticals (Hubei) focuses on the development, manufacturing, and commercialization of a wide range of innovative and generic pharmaceuticals across key therapeutic areas, including respiratory, severe anti-infection, cardiovascular, and oncology. Its pipeline includes products such as linaclotide capsules for constipation-related disorders and dotinurad tablets for hyperuricemia and gout, spanning clinical development to the NDA stage. The company is committed to high-quality standards and digital transformation, implementing advanced automated warehousing and control systems to ensure strict GMP compliance.